UOC
TRML

UBS O'Connor’s Tourmaline Bio TRML Stock Holding History

UBS O'Connor’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,000
Closed -$345K – 632
2024
Q1 		$345K Buy
+20,000
New +$705K 0.01% 361

Other funds holding TRML

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

UBS O'Connor's TRML Position: Q2 2025 in Review

UBS O'Connor sold out of Tourmaline Bio (TRML) in Q2 2025, closing a stake of 17,860 shares — an estimated $272K sold.

UBS O'Connor first reported a position in TRML in Q1 2025 and held it in 1 quarter. The position peaked at $272K in Q1 2025. 108 funds tracked by Wall St. Rank hold TRML as of Q2 2025.

  • UBS O'Connor reported no remaining Tourmaline Bio position as of Q2 2025 after selling out during the quarter.
  • UBS O'Connor sold 17,860 Tourmaline Bio shares in Q2 2025, an estimated $272K.
  • UBS O'Connor first reported a position in Tourmaline Bio in Q1 2025 and held it in 1 quarter.
  • UBS O'Connor's Tourmaline Bio position peaked at $272K in Q1 2025.
  • 108 funds tracked by Wall St. Rank held Tourmaline Bio as of Q2 2025.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.